Opella Egypt has committed approximately EGP 1 billion in total investments over the last decade to scale its presence in the local healthcare market, emphasizing a shift toward localized manufacturing and a diversified self-care portfolio.
The global self-care entity currently serves between 15 million and 20 million Egyptian patients annually. To maintain this reach, the company utilizes a flexible contract manufacturing strategy, partnering with three Egyptian firms. This model has enabled Opella to produce roughly 90% of its product range within the country, providing a buffer against supply chain disruptions and allowing the company to scale production during periods of high demand.
Egypt now accounts for approximately 18.4% of Opella’s total turnover across the Africa, Middle East and Turkey (AMET) region. Ahmed El Kamhawy, Country Head of Opella Egypt, stated that the dual-sourcing contract model allows the organization to remain agile and secure business continuity across various facilities.
Market Position and Portfolio Expansion
The company’s local operations are centered around 15 global “hero” brands. Among these, the allergy medication Telfast serves as the primary revenue driver, commanding an 18.2% market share and ranking as the top allergy brand in Egypt. Other key products, including Enterogermina, Doliprane, Bronchicum, and Maxilase, maintain positions within the top three of their respective therapeutic categories.
Looking toward 2026, Opella plans to further integrate with the Egyptian Drug Authority (EDA) to accelerate the delivery of innovative therapies to the market and expand its local production capabilities. These efforts are intended to solidify Egypt’s role as a strategic hub for the company’s regional growth.
Corporate Structure and Financial Outlook
Following its separation from Sanofi, Opella now operates as an independent self-care business. The company is jointly owned by Bpifrance, Sanofi, and CD&R. El Kamhawy noted that the establishment of an independent headquarters in Egypt has increased the company’s autonomy, allowing for strategies that are more closely tailored to local market realities even as retaining the scientific heritage of Sanofi.
Despite its operational scale, the company has ruled out an immediate initial public offering (IPO) on the Egyptian Exchange (EGX). Management indicated that the current priority is the expansion of the brand footprint and the reinforcement of local partnerships rather than a stock market listing. Similarly, while the company acknowledges the potential for regional exports, the immediate focus remains on the domestic market, where it produces 58 million packs annually.
Youth Development and Sustainability Initiatives
Opella has integrated professional development into its local strategy through the UpGrads program, which connects academic learning with industry experience. The initiative grew in 2025 to include approximately 100 students and is scheduled for further expansion in 2026.
In coordination with the Egyptian Drug Authority, the company similarly operates UpGrads Pro. This program provides final-year pharmacy students with mentorship and on-the-job exposure in marketing and sales, aligning with the national mandatory training requirements for pharmacy graduates.
On the environmental front, Opella is collaborating with Geocycle Egypt to develop eco-friendly packaging solutions. This partnership is part of a broader roadmap to implement circular economy practices within the Egyptian healthcare sector.
